levels of the hormone FGF23 in healthy volunteers with a low phosphate level

FGF23 response in hypophosphatemia

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-002602-39-NL

Enrollment

Unknown

Registered

2016-07-18

Start date

2016-10-25

Completion date

Unknown

Last updated

2016-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers the information of this pilot study will be used in the care of patients with hypophosphatemia due to renal phosphate wasting

Interventions

Trade Name: lathanum carbonate (Fosrenol) Product Name: Fosrenol Product Code: SUB21835 Pharmaceutical Form: Chewable tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age older than 18 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: any medical history inability to give informed consent pregnancy medication use (except from oral contraceptives)

Design outcomes

Primary

Measure	Time frame
Main Objective: to determine if serum FGF23 levels are affected by hypophospatemia;Secondary Objective: not applicable;Primary end point(s): serum levels of FGF23 and serum phosphate;Timepoint(s) of evaluation of this end point: monday, tuesday, wednesday, thursday, friday	—

Secondary

Measure	Time frame
Secondary end point(s): serum calcium, PTH, 1.25OHD, 25OHD, FePi;Timepoint(s) of evaluation of this end point: monday, tuesday, wednesday, thursday, friday	—

Countries

Netherlands

Contacts

Public ContactSecretariaat Nierziekten

Radboud University Medical Center

0031243614761

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026